A Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ATG 037 Monotherapy and Combination Therapy With Pembrolizumab in Patients With Advanced Solid Tumors

Brief Summary

This is a study of ATG-037 Monotherapy and Combination Therapy with Pembrolizumab in Patients with Locally or Metastatic Solid Tumors.

Provision of signed and dated, written informed consent prior to any study-specific procedures, sampling, and analyses.
Aged at least 18 years as of the date of consent.
Histological or cytological confirmation of a solid tumor that has relapsed from or refractory to standard therapies.
There is at least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
Estimated life expectancy of a minimum of 12 weeks.
Subjects with acquired immune checkpoint inhibitors resistance (objective response or SD>6 months).
Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 at ICF signature.
Females should be using adequate contraceptive measures until 180 days after the end of treatment, should not be breastfeeding.
Male subjects should be willing to use barrier contraception, ie condoms, for the duration of the study and 180 days after the final dose of study treatment.
Subjects should have adequate organ function.